We showed that bortezomib, which is used clinically to treat multiple myeloma and mantle cell lymphoma by potently blocking the 20S proteasome with an IC50 of 2.3 nM, also inhibits LonP1 with an IC50 of 17 nM for LonP1 (6). Here, LONP1 is linked to mantle cell lymphoma.